1
Clinical Neuroscience Research Unit
Connecticut Mental Health Center
34 Park Street
New Haven, CT 06519
1 of 3
- Clinical Neuroscience Research UnitConnecticut Mental Health Center34 Park StreetNew Haven, CT 06519
- Yale Depression Research Clinic100 York StreetSte 2JNew Haven, CT 06511
- Interventional PsychiataryYale New Haven Hospital - West Pavilion1 Park StreetNew Haven, CT 06510
Gerard Sanacora, PhD, MD
Psychiatry
Telehealth is available
Patient type treated
Child, Adult
Accepting new patients
No
Referral required
Not Applicable
Board Certified in
Psychiatry
Biography
Dr. Sanacora is a Professor of Psychiatry at Yale University and the Director of the Yale Depression Research Program. Dr. Sanacora’s work has focused largely on elucidating the pathophysiological mechanisms associated with mood and other neuropsychiatric disorders and using this information to inform the development of novel treatment strategies. His preclinical research laboratory explores the effects of stress and pharmaceutical agents on cellular biology, neurophysiology and behavior. His clinical laboratory employs novel imaging methodologies to investigate the pathophysiology of mood and other neuropsychiatric disorders. In addition, he has served as principal investigator on several large clinical trials investigating the efficacy and safety of newly developed therapeutic agents for the treatment of mood disorders. Dr. Sanacora received the Anna-Monkia Stiftung international award for the investigation of the biological substrate and functional disturbances of depression in 2009, the Joel Elkes Research Award for Outstanding contributions to Psychopharmacology from the American College of Neuropsychopharmacology (ACNP) in 2011, and is a Fellow of the ACNP.
Titles
- George D. and Esther S. Gross Professor of Psychiatry
- Director, Yale Depression Research Program
- Co-Director, Yale New Haven Hospital Interventional Psychiatry Service
Education & Training
- FellowYale University School of Medicine (1999)
- ResidentYale University School of Medicine (1998)
- MDSUNY at Stonybrook (1994)
- PhDSUNY at Stonybrook (1992)
- Post DoctoralSUNY Stony Brook (1992)
Additional Information
Honors & Recognitions
- Team Science Award: Association for Clinical and Translational Science (ACTS) (2022)
- Joel Elkes Research Award for outstanding contributions to Psychopharmacology: American College of Neuropsychopharmacology (2011)
- ANNA-MONIKA-FOUNDATION Award for the investigation of the biological substrate and functional disturbances of depression: ANNA-MONIKA-FOUNDATION (2009)
- Klerman Award, Honorable Mention Breakthroughs in Basic Brian & Behavior Science: NARSAD (2005)
- Klerman Award, Honorable Mention Outstanding Research Project: NARSAD (2003)
Publications
- Franklin C, Achtyes E, Altinay M, Bailey K, Bhati M, Carr B, Conroy S, Husain M, Khurshid K, Lencz T, McDonald W, Mickey B, Murrough J, Nestor S, Nickl-Jockschat T, Nikayin S, Reeves K, Reti I, Selek S, Sanacora G, Trapp N, Viswanath B, Wright J, Sullivan P, Zandi P, Potash J. The genetics of severe depression. Molecular Psychiatry 2024, 1-10. PMID: 39406997, DOI: 10.1038/s41380-024-02731-1.
- Ansari M, Sanacora G. The Role of Awe and Other Psychological Factors in Ketamine’s Mechanism of Antidepressant Action. Biological Psychiatry Global Open Science 2024, 4: 100353. DOI: 10.1016/j.bpsgos.2024.100353.
- Jha M, Wilkinson S, Krishnan K, Collins K, Sanacora G, Murrough J, Goes F, Altinay M, Aloysi A, Asghar-Ali A, Barnett B, Chang L, Costi S, Malone D, Nikayin S, Nissen S, Ostroff R, Reti I, Wolski K, Wang D, Hu B, Mathew S, Anand A. Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression. JAMA Network Open 2024, 7: e2417786. PMID: 38916891, PMCID: PMC11200139, DOI: 10.1001/jamanetworkopen.2024.17786.
- Cristancho M, Fava M, Ingelfinger J, Nikayin S, Sanacora G. Depression - Advanced Treatments for Treatment-Resistant Depression. New England Journal Of Medicine 2024, 390: e44. PMID: 38810184, DOI: 10.1056/nejmp2310181.
- Anderson E, Crawford C, Fava M, Ingelfinger J, Sanacora G, Scott-Vernaglia S, Teel J. Depression - Treatment Options and Managing Depression in Primary Care. New England Journal Of Medicine 2024, 390: e44. PMID: 38749042, DOI: 10.1056/nejmp2310180.
- Anderson E, Crawford C, Fava M, Ingelfinger J, Nikayin S, Sanacora G, Scott-Vernaglia S, Teel J. Depression - Understanding, Identifying, and Diagnosing. New England Journal Of Medicine 2024, 390: e41. PMID: 38692291, DOI: 10.1056/nejmp2310179.
- Codeluppi S, Xu M, Bansal Y, Lepack A, Duric V, Chow M, Muir J, Bagot R, Licznerski P, Wilber S, Sanacora G, Sibille E, Duman R, Pittenger C, Banasr M. 497. Prefrontal Cortex Astroglia Modulate Anhedonia-Like Behavior. Biological Psychiatry 2024, 95: s302. DOI: 10.1016/j.biopsych.2024.02.996.
- Wilkinson S, Palamar J, Sanacora G. The Rapidly Shifting Ketamine Landscape in the US. JAMA Psychiatry 2024, 81: 221-222. PMID: 38170542, DOI: 10.1001/jamapsychiatry.2023.4945.
- Krystal J, Kaye A, Jefferson S, Girgenti M, Wilkinson S, Sanacora G, Esterlis I. Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2305772120. PMID: 38011560, PMCID: PMC10710048, DOI: 10.1073/pnas.2305772120.
- Rhee T, Davoudian P, Sanacora G, Wilkinson S. Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders. Drug Discovery Today 2023, 28: 103818. PMID: 37925136, DOI: 10.1016/j.drudis.2023.103818.
- Kitay B, Murphy E, Macaluso M, Corlett P, Hershenberg R, Joormann J, Martinez-Kaigi V, Nikayin S, Rhee T, Sanacora G, Shelton R, Thase M, Wilkinson S. Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol. Psychiatry Research 2023, 330: 115585. PMID: 37935086, DOI: 10.1016/j.psychres.2023.115585.
- Sanacora G, Colloca L. Placebo’s role in the rapid antidepressant effect. Nature Mental Health 2023, 1: 820-821. DOI: 10.1038/s44220-023-00141-w.
- McIntyre R, Alsuwaidan M, Baune B, Berk M, Demyttenaere K, Goldberg J, Gorwood P, Ho R, Kasper S, Kennedy S, Ly-Uson J, Mansur R, McAllister-Williams R, Murrough J, Nemeroff C, Nierenberg A, Rosenblat J, Sanacora G, Schatzberg A, Shelton R, Stahl S, Trivedi M, Vieta E, Vinberg M, Williams N, Young A, Maj M. Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry 2023, 22: 394-412. PMID: 37713549, PMCID: PMC10503923, DOI: 10.1002/wps.21120.
- Codeluppi S, Xu M, Bansal Y, Lepack A, Duric V, Chow M, Muir J, Bagot R, Licznerski P, Wilber S, Sanacora G, Sibille E, Duman R, Pittenger C, Banasr M. Prefrontal cortex astroglia modulate anhedonia-like behavior. Molecular Psychiatry 2023, 28: 4632-4641. PMID: 37696873, PMCID: PMC10914619, DOI: 10.1038/s41380-023-02246-1.
- Raison C, Sanacora G, Woolley J, Heinzerling K, Dunlop B, Brown R, Kakar R, Hassman M, Trivedi R, Robison R, Gukasyan N, Nayak S, Hu X, O’Donnell K, Kelmendi B, Sloshower J, Penn A, Bradley E, Kelly D, Mletzko T, Nicholas C, Hutson P, Tarpley G, Utzinger M, Lenoch K, Warchol K, Gapasin T, Davis M, Nelson-Douthit C, Wilson S, Brown C, Linton W, Johnson M, Ross S, Griffiths R. Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA 2023, 330: 843-853. PMID: 37651119, PMCID: PMC10472268, DOI: 10.1001/jama.2023.14530.
- Colloca L, Nikayin S, Sanacora G. The Intricate Interaction Between Expectations and Therapeutic Outcomes of Psychedelic Agents. JAMA Psychiatry 2023, 80: 867-868. PMID: 37405764, PMCID: PMC10868530, DOI: 10.1001/jamapsychiatry.2023.1412.
- Darrow S, Pizzagalli D, Smoski M, Mathew S, Nurnberger J, Lisanby S, Iosifescu D, Murrough J, Yang H, Weiner R, Sanacora G, Keefe R, Song A, Goodman W, Whitton A, Potter W, Krystal A. Using latent profile analyses to classify subjects with anhedonia based on reward-related measures obtained in the FAST-MAS study. Journal Of Affective Disorders 2023, 339: 584-592. PMID: 37467805, DOI: 10.1016/j.jad.2023.07.081.
- Anand A, Mathew S, Sanacora G, Murrough J, Goes F, Altinay M, Aloysi A, Asghar-Ali A, Barnett B, Chang L, Collins K, Costi S, Iqbal S, Jha M, Krishnan K, Malone D, Nikayin S, Nissen S, Ostroff R, Reti I, Wilkinson S, Wolski K, Hu B. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. New England Journal Of Medicine 2023, 388: 2315-2325. PMID: 37224232, DOI: 10.1056/nejmoa2302399.
- Zaki N, Chen L, Lane R, Doherty T, Drevets W, Morrison R, Sanacora G, Wilkinson S, Popova V, Fu D. Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Neuropsychopharmacology 2023, 48: 1225-1233. PMID: 37173512, PMCID: PMC10267177, DOI: 10.1038/s41386-023-01577-5.
- Abi-Dargham A, Moeller S, Ali F, DeLorenzo C, Domschke K, Horga G, Jutla A, Kotov R, Paulus M, Rubio J, Sanacora G, Veenstra-VanderWeele J, Krystal J. Candidate biomarkers in psychiatric disorders: state of the field. World Psychiatry 2023, 22: 236-262. PMID: 37159365, PMCID: PMC10168176, DOI: 10.1002/wps.21078.
- Leal G, Souza-Marques B, Mello R, Bandeira I, Caliman-Fontes A, Carneiro B, Faria-Guimarães D, Guerreiro-Costa L, Jesus-Nunes A, Silva S, Lins-Silva D, Fontes M, Alves-Pereira R, Cordeiro V, Rugieri-Pacheco S, Santos-Lima C, Correia-Melo F, Vieira F, Sanacora G, Lacerda A, Quarantini L. Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study. Journal Of Affective Disorders 2023, 330: 7-15. PMID: 36871913, DOI: 10.1016/j.jad.2023.02.151.
- Bansal Y, Fee C, Misquitta K, Codeluppi S, Sibille E, Berman R, Coric V, Sanacora G, Banasr M. Prophylactic Efficacy of Riluzole against Anxiety- and Depressive-Like Behaviors in Two Rodent Stress Models. Complex Psychiatry 2023, 9: 57-69. PMID: 37101541, PMCID: PMC10123365, DOI: 10.1159/000529534.
- Young A, Zaki N, Chen N, Lane R, Doherty T, Drevets W, Morrison R, Sanacora G, Wilkinson S, Lacerda A, Popova V, Fu D. Long-term safety and maintenance of response with esketamine nasal spray in treatment-resistant depression – final results of the SUSTAIN-3 study. Neuroscience Applied 2023, 2: 102450. DOI: 10.1016/j.nsa.2023.102450.
- Feeney A, Hoeppner B, Freeman M, Flynn M, Iosifescu D, Trivedi M, Sanacora G, Mathew S, DeBattista C, Ionescu D, Cusin C, Papakostas G, Jha M, Fava M. Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study. The Journal Of Clinical Psychiatry 2022, 84 PMID: 36383742, DOI: 10.4088/jcp.22m14491.
- Feeney A, Hoeppner B, Freeman M, Flynn M, Iosifescu D, Trivedi M, Sanacora G, Mathew S, DeBattista C, Ionescu D, Cusin C, Papakostas G, Jha M, Fava M. Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine. The Journal Of Clinical Psychiatry 2022, 84 DOI: 10.4088/jcp.22m14991.
- Holmes S, Asch R, Davis M, DellaGioia N, Pashankar N, Gallezot J, Nabulsi N, Matuskey D, Sanacora G, Carson R, Blumberg H, Esterlis I. Differences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder. Biological Psychiatry 2022, 93: 1099-1107. PMID: 36764853, PMCID: PMC10164841, DOI: 10.1016/j.biopsych.2022.10.018.
- Dwyer J, Landeros-Weisenberger A, Johnson J, Londono Tobon A, Flores J, Nasir M, Couloures K, Sanacora G, Bloch M. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. FOCUS The Journal Of Lifelong Learning In Psychiatry 2022, 20: 241-251. PMID: 37153136, PMCID: PMC10153503, DOI: 10.1176/appi.focus.22020004.
- Levey DF, Stein MB, Wendt FR, Pathak GA, Zhou H, Aslan M, Quaden R, Harrington KM, Nuñez YZ, Overstreet C, Radhakrishnan K, Sanacora G, McIntosh AM, Shi J, Shringarpure SS, Concato J, Polimanti R, Gelernter J. Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions. Nature Neuroscience 2021, 24: 954-963. PMID: 34045744, PMCID: PMC8404304, DOI: 10.1038/s41593-021-00860-2.
- Krystal A, Pizzagalli D, Smoski M, Mathew S, Nurnberger J, Lisanby S, Iosifescu D, Murrough J, Weiner R, Calabrese J, Sanacora G, Keefe R, Song A, Goodman W, Szabo S, Whitten A, Gao K, Potter W. 116. Results of the NIMH FAST-MAS Phase IIa Proof of Mechanism Study of the Effects of the Selective κ Opioid Antagonist JNJ-67953964 on fMRI Ventral Striatal Activity in Anhedonic Patients. Biological Psychiatry 2019, 85: s48-s49. DOI: 10.1016/j.biopsych.2019.03.130.
- Webler R, Wilkinson S, Kirwin D, Bloch M, Kitay B, Sanacora G. S128. Expectancy and Ketamine’s Rapid Antidepressant Effect: A Meta-Analysis. Biological Psychiatry 2019, 85: s346. DOI: 10.1016/j.biopsych.2019.03.879.
- Ochs-Ross R, Daly E, Zhang Y, Lane R, Lim P, Foster K, Hough D, Manji H, Drevets W, Sanacora G, Adler C, McShane R, Gaillard R, Singh J. EFFICACY AND SAFETY OF ESKETAMINE NASAL SPRAY PLUS AN ORAL ANTIDEPRESSANT IN ELDERLY PATIENTS WITH TREATMENT-RESISTANT DEPRESSION. American Journal Of Geriatric Psychiatry 2019, 27: s139-s140. DOI: 10.1016/j.jagp.2019.01.093.
- Ochs-Ross R, Daly E, Zhang Y, Lane R, Lim P, Foster K, Hough D, Manji H, Drevets W, Sanacora G, Adler C, McShane R, Gaillard R, Singh J. POST HOC ANALYSES OF ESKETAMINE NASAL SPRAY PLUS AN ORAL ANTIDEPRESSANT IN ELDERLY PATIENTS WITH TREATMENT-RESISTANT DEPRESSION. American Journal Of Geriatric Psychiatry 2019, 27: s140-s141. DOI: 10.1016/j.jagp.2019.01.094.
- Ochs-Ross R, Daly E, Zhang Y, Lane R, Lim P, Foster K, Hough D, Manji H, Drevets W, Sanacora G, Adler C, McShane R, Gaillard R, Singh J. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression. European Neuropsychopharmacology 2019, 29: s355-s356. DOI: 10.1016/j.euroneuro.2018.11.548.
- Wajs E, Leah A, Morrison R, Daly E, Lane R, Lim P, Holder R, Sanacora G, Young A, Kasper S, Sulaiman A, Li C, Paik J, Manji H, Hough D, Drevets W, Singh J. Long-term safety of esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: SUSTAIN-2 phase 3 study. European Neuropsychopharmacology 2019, 29: s44-s45. DOI: 10.1016/j.euroneuro.2018.11.1016.
- Sanacora G, Kitay B, Wilkinson S. Chapter 35 The Search for Rapid Acting Antidepressants: Research Synthesis and Perspectives. 2019, 401-413. DOI: 10.1016/b978-0-12-813333-0.00035-4.
- Wajs E, Aluisio L, Morrison R, Daly E, Lane R, Lim P, Holder R, Sanacora G, Young A, Kasper S, Sulaiman A, Li C, Paik J, Manji H, Hough D, Drevets W, Singh J. Etude de phase 3 en ouvert évaluant l’efficacité et la sécurité d’emploi à long terme d’Eskétamine intranasal (ESK IN) associé à un antidépresseur oral chez des patients atteints de dépression résistante (SUSTAIN-2). French Journal Of Psychiatry 2018, 1: s176. DOI: 10.1016/s2590-2415(19)30445-3.
- Ochs-Ross R, Daly E, Zhang Y, Lane R, Lim P, Foster K, Hough D, Manji H, Drevets W, Sanacora G, Adler C, McShane R, Gaillard R, Singh J. S114. Efficacy and Safety of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression. Biological Psychiatry 2018, 83: s391. DOI: 10.1016/j.biopsych.2018.02.1005.
- Wilkinson S, Webler R, Katz R, Toprak M, Ostroff R, Sanacora G. S106. Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital. Biological Psychiatry 2018, 83: s388. DOI: 10.1016/j.biopsych.2018.02.997.
- Sanacora G, Wilkinson S, Van Schalkwyk G. 201 Measuring Dissociative Effects of NMDA Receptor Antagonists in the Treatment of Depression. Biological Psychiatry 2017, 81: s83. DOI: 10.1016/j.biopsych.2017.02.214.
- Dwyer J, Sanacora G, Bloch M. 1002 Ketamine as a Treatment for Adolescent Major Depressive Disorder. Biological Psychiatry 2017, 81: s405. DOI: 10.1016/j.biopsych.2017.02.729.
- Sanacora G, Chowdhury G, Rothman D, Behar K. 662 Ketamine and Rapastinel Effects on Glutamate Cycling. Biological Psychiatry 2017, 81: s268. DOI: 10.1016/j.biopsych.2017.02.1071.
- Ostroff R, Wilkinson S, Sanacora G. Computer-assisted cognitive behavior therapy to prevent relapse following electroconvulsive therapy. Brain Stimulation 2017, 10: 524. DOI: 10.1016/j.brs.2017.01.529.
- Hermes G, Sanacora G. Ketamine’s Mechanisms of Rapid Antidepressant Activity: Evidence from Preclinical Studies. 2016, 73-98. DOI: 10.1007/978-3-319-42925-0_6.
- Sanacora G, Heimer H, Hartman D, Mathew S, Frye M, Nemeroff C, Robinson Beale R. Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders. Neuropsychopharmacology 2016, 42: 1179-1181. PMID: 27640324, PMCID: PMC5437876, DOI: 10.1038/npp.2016.193.
- Krystal J, Sanacora G, Abdallah C, Duman R. Speaker 4: John Krystal, USA. The International Journal Of Neuropsychopharmacology 2016, 19: 19-19. PMCID: PMC5616528, DOI: 10.1093/ijnp/pyw042.052.
- Singh J, Fedgchin M, Daly E, De Boer P, Cooper K, Lim P, Pinter C, Murrough J, Sanacora G, Shelton R, Kurian B, Winokur A, Fava M, Manji H, Drevets W, Van Nueten L. P.2.b.017 Onset of efficacy of ketamine in treatment-resistant depression: a double-blind, randomised, placebo-controlled, dose frequency study. European Neuropsychopharmacology 2014, 24: s387-s388. DOI: 10.1016/s0924-977x(14)70618-2.
- Kiselycznyk C, Sanacora G. Using Our Understanding of Stress-Related Effects on Glutamate Neurotransmission to Guide the Development of Novel Treatment Strategies. 2014, 313-341. DOI: 10.1007/978-1-4939-1056-4_17.
- Sanacora G, Duman R. The Revolution in Rapid-Acting Antidepressants. Biological Psychiatry 2013, 73: 1123-1124. DOI: 10.1016/j.biopsych.2013.04.020.
- Abdallah CG, Fasula M, Kelmendi B, Sanacora G, Ostroff R. Rapid Antidepressant Effect of Ketamine in the Electroconvulsive Therapy Setting. Journal Of Ect 2012, 28: 157-161. PMID: 22847373, PMCID: PMC3426617, DOI: 10.1097/yct.0b013e31824f8296.
- Laje G, Lally N, Mathews D, Brutsche N, Chemerinski A, Akula N, Kelmendi B, Simen A, McMahon FJ, Sanacora G, Zarate C. Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Antidepressant Efficacy of Ketamine in Depressed Patients. Biological Psychiatry 2012, 72: e27-e28. PMID: 22771240, PMCID: PMC3786174, DOI: 10.1016/j.biopsych.2012.05.031.
- Morgan PT, Pace-Schott EF, Mason GF, Forselius E, Fasula M, Valentine GW, Sanacora G. Cortical GABA Levels in Primary Insomnia. Sleep 2012, 35: 807-814. PMID: 22654200, PMCID: PMC3353043, DOI: 10.5665/sleep.1880.
- Chowdhury GM, Behar KL, Cho W, Thomas MA, Rothman DL, Sanacora G. 1H-[13C]-Nuclear Magnetic Resonance Spectroscopy Measures of Ketamine's Effect on Amino Acid Neurotransmitter Metabolism. Biological Psychiatry 2011, 71: 1022-1025. PMID: 22169441, PMCID: PMC3660962, DOI: 10.1016/j.biopsych.2011.11.006.
- Popoli M, Yan Z, McEwen BS, Sanacora G. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nature Reviews Neuroscience 2011, 13: 22-37. PMID: 22127301, PMCID: PMC3645314, DOI: 10.1038/nrn3138.
- Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B, Krystal JH, Sanacora G. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS. Psychiatry Research 2011, 191: 122-127. PMID: 21232924, PMCID: PMC3061550, DOI: 10.1016/j.pscychresns.2010.10.009.
- Sanacora G, Banasr M, Chowdhury G, Lepak A, Behar K. S.28.05 Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioural deficits by the glutamate-modulating drug riluzole. European Neuropsychopharmacology 2010, 20: s208. DOI: 10.1016/s0924-977x(10)70241-8.
- Banasr M, Chowdhury GM, Terwilliger R, Newton SS, Duman RS, Behar KL, Sanacora G. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Molecular Psychiatry 2008, 15: 501-511. PMID: 18825147, PMCID: PMC3347761, DOI: 10.1038/mp.2008.106.
- Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews Drug Discovery 2008, 7: 426-437. PMID: 18425072, PMCID: PMC2715836, DOI: 10.1038/nrd2462.
- Neumeister A, Charney D, Sanacora G, Krystal J. Neurobiology and Treatment of Depression. 2007 DOI: 10.1002/9780470101001.hcn018.
- Sanacora G. Evidence for GABAergic and Glutamatergic Involvement in the Pathophysiology and Treatment of Depressive Disorders. 2002, 739-749. DOI: 10.1002/0470854871.chxviii3.
- Krystal J, D'Souza D, Sanacora G, Goddard A, Charney D. CURRENT PERSPECTIVES ON THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA, DEPRESSION, AND ANXIETY DISORDERS. Medical Clinics Of North America 2001, 85: 559-577. PMID: 11349473, DOI: 10.1016/s0025-7125(05)70329-1.
- Chen A, Shin K, Duman R, Sanacora G. ECS-Induced Mossy Fiber Sprouting and BDNF Expression Are Attenuated By Ketamine Pretreatment. Journal Of Ect 2001, 17: 27-32. PMID: 11281511, DOI: 10.1097/00124509-200103000-00006.
- Berman R, Sanacora G, Narasimhan M, Oren D, Cappiello A, Charney D. 268. Simultaneous catecholamine and indoleamine depletion in unmedicated depressed subjects. Biological Psychiatry 2000, 47: s81. DOI: 10.1016/s0006-3223(00)00532-1.
- Berman R, Narasimhan M, Sanacora G, Miano A, Hoffman R, Hu X, Charney D, Boutros N. A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression. Biological Psychiatry 2000, 47: 332-337. PMID: 10686268, DOI: 10.1016/s0006-3223(99)00243-7.
- Sanacora G, Mason G, Krystal J. Impairment of GABAergic Transmission in Depression: New Insights from Neuroimaging Studies. Critical Reviews In Neurobiology 2000, 14: 23. PMID: 11253954, DOI: 10.1615/critrevneurobiol.v14.i1.20.
- Sanacora G, Rothman D, Krystal J. Applications of Magnetic Resonance Spectroscopy to Psychiatry. The Neuroscientist 1999, 5: 192-196. DOI: 10.1177/107385849900500316.
- Sanacora G, Chen A, Shin K, Duman R. 8. Ketamine Effects on ECS Induced BDNF Expression and Mossy Fiber Sprouting. Journal Of Ect 1999, 15: 109. DOI: 10.1097/00124509-199903000-00028.
- Sanacora G, Mason G, Rothman D, Berman R, Charney D, Ciarcia J, Krystal J. 1. ECT Effects on Cortical GABA Levels as Determined by 1H-MRS. Journal Of Ect 1999, 15: 102. DOI: 10.1097/00124509-199903000-00009.
- Malison R, Price L, Berman R, van Dyck C, Pelton G, Carpenter L, Sanacora G, Owens M, Nemeroff C, Rajeevan N, Baldwin R, Seibyl J, Innis R, Charney D. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography. Biological Psychiatry 1998, 44: 1090-1098. PMID: 9836013, DOI: 10.1016/s0006-3223(98)00272-8.
- Berman R, Boutros N, Narasimhan M, Sanacora G, Charney D. 322. Transcranial magnetic stimulation in treatment-refractory depression. Biological Psychiatry 1998, 43: s97. DOI: 10.1016/s0006-3223(98)90770-3.
Departments and Programs
Locations
1
Clinical Neuroscience Research Unit
Connecticut Mental Health Center
34 Park Street
New Haven, CT 06519
1 of 3
- Clinical Neuroscience Research UnitConnecticut Mental Health Center34 Park StreetNew Haven, CT 06519
- Yale Depression Research Clinic100 York StreetSte 2JNew Haven, CT 06511
- Interventional PsychiataryYale New Haven Hospital - West Pavilion1 Park StreetNew Haven, CT 06510
Biography
Dr. Sanacora is a Professor of Psychiatry at Yale University and the Director of the Yale Depression Research Program. Dr. Sanacora’s work has focused largely on elucidating the pathophysiological mechanisms associated with mood and other neuropsychiatric disorders and using this information to inform the development of novel treatment strategies. His preclinical research laboratory explores the effects of stress and pharmaceutical agents on cellular biology, neurophysiology and behavior. His clinical laboratory employs novel imaging methodologies to investigate the pathophysiology of mood and other neuropsychiatric disorders. In addition, he has served as principal investigator on several large clinical trials investigating the efficacy and safety of newly developed therapeutic agents for the treatment of mood disorders. Dr. Sanacora received the Anna-Monkia Stiftung international award for the investigation of the biological substrate and functional disturbances of depression in 2009, the Joel Elkes Research Award for Outstanding contributions to Psychopharmacology from the American College of Neuropsychopharmacology (ACNP) in 2011, and is a Fellow of the ACNP.
Titles
- George D. and Esther S. Gross Professor of Psychiatry
- Director, Yale Depression Research Program
- Co-Director, Yale New Haven Hospital Interventional Psychiatry Service
Education & Training
- FellowYale University School of Medicine (1999)
- ResidentYale University School of Medicine (1998)
- MDSUNY at Stonybrook (1994)
- PhDSUNY at Stonybrook (1992)
- Post DoctoralSUNY Stony Brook (1992)
Additional Information
Honors & Recognitions
- Team Science Award: Association for Clinical and Translational Science (ACTS) (2022)
- Joel Elkes Research Award for outstanding contributions to Psychopharmacology: American College of Neuropsychopharmacology (2011)
- ANNA-MONIKA-FOUNDATION Award for the investigation of the biological substrate and functional disturbances of depression: ANNA-MONIKA-FOUNDATION (2009)
- Klerman Award, Honorable Mention Breakthroughs in Basic Brian & Behavior Science: NARSAD (2005)
- Klerman Award, Honorable Mention Outstanding Research Project: NARSAD (2003)
Publications
- Franklin C, Achtyes E, Altinay M, Bailey K, Bhati M, Carr B, Conroy S, Husain M, Khurshid K, Lencz T, McDonald W, Mickey B, Murrough J, Nestor S, Nickl-Jockschat T, Nikayin S, Reeves K, Reti I, Selek S, Sanacora G, Trapp N, Viswanath B, Wright J, Sullivan P, Zandi P, Potash J. The genetics of severe depression. Molecular Psychiatry 2024, 1-10. PMID: 39406997, DOI: 10.1038/s41380-024-02731-1.
- Ansari M, Sanacora G. The Role of Awe and Other Psychological Factors in Ketamine’s Mechanism of Antidepressant Action. Biological Psychiatry Global Open Science 2024, 4: 100353. DOI: 10.1016/j.bpsgos.2024.100353.
- Jha M, Wilkinson S, Krishnan K, Collins K, Sanacora G, Murrough J, Goes F, Altinay M, Aloysi A, Asghar-Ali A, Barnett B, Chang L, Costi S, Malone D, Nikayin S, Nissen S, Ostroff R, Reti I, Wolski K, Wang D, Hu B, Mathew S, Anand A. Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression. JAMA Network Open 2024, 7: e2417786. PMID: 38916891, PMCID: PMC11200139, DOI: 10.1001/jamanetworkopen.2024.17786.
- Cristancho M, Fava M, Ingelfinger J, Nikayin S, Sanacora G. Depression - Advanced Treatments for Treatment-Resistant Depression. New England Journal Of Medicine 2024, 390: e44. PMID: 38810184, DOI: 10.1056/nejmp2310181.
- Anderson E, Crawford C, Fava M, Ingelfinger J, Sanacora G, Scott-Vernaglia S, Teel J. Depression - Treatment Options and Managing Depression in Primary Care. New England Journal Of Medicine 2024, 390: e44. PMID: 38749042, DOI: 10.1056/nejmp2310180.
- Anderson E, Crawford C, Fava M, Ingelfinger J, Nikayin S, Sanacora G, Scott-Vernaglia S, Teel J. Depression - Understanding, Identifying, and Diagnosing. New England Journal Of Medicine 2024, 390: e41. PMID: 38692291, DOI: 10.1056/nejmp2310179.
- Codeluppi S, Xu M, Bansal Y, Lepack A, Duric V, Chow M, Muir J, Bagot R, Licznerski P, Wilber S, Sanacora G, Sibille E, Duman R, Pittenger C, Banasr M. 497. Prefrontal Cortex Astroglia Modulate Anhedonia-Like Behavior. Biological Psychiatry 2024, 95: s302. DOI: 10.1016/j.biopsych.2024.02.996.
- Wilkinson S, Palamar J, Sanacora G. The Rapidly Shifting Ketamine Landscape in the US. JAMA Psychiatry 2024, 81: 221-222. PMID: 38170542, DOI: 10.1001/jamapsychiatry.2023.4945.
- Krystal J, Kaye A, Jefferson S, Girgenti M, Wilkinson S, Sanacora G, Esterlis I. Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2305772120. PMID: 38011560, PMCID: PMC10710048, DOI: 10.1073/pnas.2305772120.
- Rhee T, Davoudian P, Sanacora G, Wilkinson S. Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders. Drug Discovery Today 2023, 28: 103818. PMID: 37925136, DOI: 10.1016/j.drudis.2023.103818.
- Kitay B, Murphy E, Macaluso M, Corlett P, Hershenberg R, Joormann J, Martinez-Kaigi V, Nikayin S, Rhee T, Sanacora G, Shelton R, Thase M, Wilkinson S. Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol. Psychiatry Research 2023, 330: 115585. PMID: 37935086, DOI: 10.1016/j.psychres.2023.115585.
- Sanacora G, Colloca L. Placebo’s role in the rapid antidepressant effect. Nature Mental Health 2023, 1: 820-821. DOI: 10.1038/s44220-023-00141-w.
- McIntyre R, Alsuwaidan M, Baune B, Berk M, Demyttenaere K, Goldberg J, Gorwood P, Ho R, Kasper S, Kennedy S, Ly-Uson J, Mansur R, McAllister-Williams R, Murrough J, Nemeroff C, Nierenberg A, Rosenblat J, Sanacora G, Schatzberg A, Shelton R, Stahl S, Trivedi M, Vieta E, Vinberg M, Williams N, Young A, Maj M. Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry 2023, 22: 394-412. PMID: 37713549, PMCID: PMC10503923, DOI: 10.1002/wps.21120.
- Codeluppi S, Xu M, Bansal Y, Lepack A, Duric V, Chow M, Muir J, Bagot R, Licznerski P, Wilber S, Sanacora G, Sibille E, Duman R, Pittenger C, Banasr M. Prefrontal cortex astroglia modulate anhedonia-like behavior. Molecular Psychiatry 2023, 28: 4632-4641. PMID: 37696873, PMCID: PMC10914619, DOI: 10.1038/s41380-023-02246-1.
- Raison C, Sanacora G, Woolley J, Heinzerling K, Dunlop B, Brown R, Kakar R, Hassman M, Trivedi R, Robison R, Gukasyan N, Nayak S, Hu X, O’Donnell K, Kelmendi B, Sloshower J, Penn A, Bradley E, Kelly D, Mletzko T, Nicholas C, Hutson P, Tarpley G, Utzinger M, Lenoch K, Warchol K, Gapasin T, Davis M, Nelson-Douthit C, Wilson S, Brown C, Linton W, Johnson M, Ross S, Griffiths R. Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA 2023, 330: 843-853. PMID: 37651119, PMCID: PMC10472268, DOI: 10.1001/jama.2023.14530.
- Colloca L, Nikayin S, Sanacora G. The Intricate Interaction Between Expectations and Therapeutic Outcomes of Psychedelic Agents. JAMA Psychiatry 2023, 80: 867-868. PMID: 37405764, PMCID: PMC10868530, DOI: 10.1001/jamapsychiatry.2023.1412.
- Darrow S, Pizzagalli D, Smoski M, Mathew S, Nurnberger J, Lisanby S, Iosifescu D, Murrough J, Yang H, Weiner R, Sanacora G, Keefe R, Song A, Goodman W, Whitton A, Potter W, Krystal A. Using latent profile analyses to classify subjects with anhedonia based on reward-related measures obtained in the FAST-MAS study. Journal Of Affective Disorders 2023, 339: 584-592. PMID: 37467805, DOI: 10.1016/j.jad.2023.07.081.
- Anand A, Mathew S, Sanacora G, Murrough J, Goes F, Altinay M, Aloysi A, Asghar-Ali A, Barnett B, Chang L, Collins K, Costi S, Iqbal S, Jha M, Krishnan K, Malone D, Nikayin S, Nissen S, Ostroff R, Reti I, Wilkinson S, Wolski K, Hu B. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. New England Journal Of Medicine 2023, 388: 2315-2325. PMID: 37224232, DOI: 10.1056/nejmoa2302399.
- Zaki N, Chen L, Lane R, Doherty T, Drevets W, Morrison R, Sanacora G, Wilkinson S, Popova V, Fu D. Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Neuropsychopharmacology 2023, 48: 1225-1233. PMID: 37173512, PMCID: PMC10267177, DOI: 10.1038/s41386-023-01577-5.
- Abi-Dargham A, Moeller S, Ali F, DeLorenzo C, Domschke K, Horga G, Jutla A, Kotov R, Paulus M, Rubio J, Sanacora G, Veenstra-VanderWeele J, Krystal J. Candidate biomarkers in psychiatric disorders: state of the field. World Psychiatry 2023, 22: 236-262. PMID: 37159365, PMCID: PMC10168176, DOI: 10.1002/wps.21078.
- Leal G, Souza-Marques B, Mello R, Bandeira I, Caliman-Fontes A, Carneiro B, Faria-Guimarães D, Guerreiro-Costa L, Jesus-Nunes A, Silva S, Lins-Silva D, Fontes M, Alves-Pereira R, Cordeiro V, Rugieri-Pacheco S, Santos-Lima C, Correia-Melo F, Vieira F, Sanacora G, Lacerda A, Quarantini L. Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study. Journal Of Affective Disorders 2023, 330: 7-15. PMID: 36871913, DOI: 10.1016/j.jad.2023.02.151.
- Bansal Y, Fee C, Misquitta K, Codeluppi S, Sibille E, Berman R, Coric V, Sanacora G, Banasr M. Prophylactic Efficacy of Riluzole against Anxiety- and Depressive-Like Behaviors in Two Rodent Stress Models. Complex Psychiatry 2023, 9: 57-69. PMID: 37101541, PMCID: PMC10123365, DOI: 10.1159/000529534.
- Young A, Zaki N, Chen N, Lane R, Doherty T, Drevets W, Morrison R, Sanacora G, Wilkinson S, Lacerda A, Popova V, Fu D. Long-term safety and maintenance of response with esketamine nasal spray in treatment-resistant depression – final results of the SUSTAIN-3 study. Neuroscience Applied 2023, 2: 102450. DOI: 10.1016/j.nsa.2023.102450.
- Feeney A, Hoeppner B, Freeman M, Flynn M, Iosifescu D, Trivedi M, Sanacora G, Mathew S, DeBattista C, Ionescu D, Cusin C, Papakostas G, Jha M, Fava M. Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study. The Journal Of Clinical Psychiatry 2022, 84 PMID: 36383742, DOI: 10.4088/jcp.22m14491.
- Feeney A, Hoeppner B, Freeman M, Flynn M, Iosifescu D, Trivedi M, Sanacora G, Mathew S, DeBattista C, Ionescu D, Cusin C, Papakostas G, Jha M, Fava M. Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine. The Journal Of Clinical Psychiatry 2022, 84 DOI: 10.4088/jcp.22m14991.
- Holmes S, Asch R, Davis M, DellaGioia N, Pashankar N, Gallezot J, Nabulsi N, Matuskey D, Sanacora G, Carson R, Blumberg H, Esterlis I. Differences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder. Biological Psychiatry 2022, 93: 1099-1107. PMID: 36764853, PMCID: PMC10164841, DOI: 10.1016/j.biopsych.2022.10.018.
- Dwyer J, Landeros-Weisenberger A, Johnson J, Londono Tobon A, Flores J, Nasir M, Couloures K, Sanacora G, Bloch M. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. FOCUS The Journal Of Lifelong Learning In Psychiatry 2022, 20: 241-251. PMID: 37153136, PMCID: PMC10153503, DOI: 10.1176/appi.focus.22020004.
- Levey DF, Stein MB, Wendt FR, Pathak GA, Zhou H, Aslan M, Quaden R, Harrington KM, Nuñez YZ, Overstreet C, Radhakrishnan K, Sanacora G, McIntosh AM, Shi J, Shringarpure SS, Concato J, Polimanti R, Gelernter J. Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions. Nature Neuroscience 2021, 24: 954-963. PMID: 34045744, PMCID: PMC8404304, DOI: 10.1038/s41593-021-00860-2.
- Krystal A, Pizzagalli D, Smoski M, Mathew S, Nurnberger J, Lisanby S, Iosifescu D, Murrough J, Weiner R, Calabrese J, Sanacora G, Keefe R, Song A, Goodman W, Szabo S, Whitten A, Gao K, Potter W. 116. Results of the NIMH FAST-MAS Phase IIa Proof of Mechanism Study of the Effects of the Selective κ Opioid Antagonist JNJ-67953964 on fMRI Ventral Striatal Activity in Anhedonic Patients. Biological Psychiatry 2019, 85: s48-s49. DOI: 10.1016/j.biopsych.2019.03.130.
- Webler R, Wilkinson S, Kirwin D, Bloch M, Kitay B, Sanacora G. S128. Expectancy and Ketamine’s Rapid Antidepressant Effect: A Meta-Analysis. Biological Psychiatry 2019, 85: s346. DOI: 10.1016/j.biopsych.2019.03.879.
- Ochs-Ross R, Daly E, Zhang Y, Lane R, Lim P, Foster K, Hough D, Manji H, Drevets W, Sanacora G, Adler C, McShane R, Gaillard R, Singh J. EFFICACY AND SAFETY OF ESKETAMINE NASAL SPRAY PLUS AN ORAL ANTIDEPRESSANT IN ELDERLY PATIENTS WITH TREATMENT-RESISTANT DEPRESSION. American Journal Of Geriatric Psychiatry 2019, 27: s139-s140. DOI: 10.1016/j.jagp.2019.01.093.
- Ochs-Ross R, Daly E, Zhang Y, Lane R, Lim P, Foster K, Hough D, Manji H, Drevets W, Sanacora G, Adler C, McShane R, Gaillard R, Singh J. POST HOC ANALYSES OF ESKETAMINE NASAL SPRAY PLUS AN ORAL ANTIDEPRESSANT IN ELDERLY PATIENTS WITH TREATMENT-RESISTANT DEPRESSION. American Journal Of Geriatric Psychiatry 2019, 27: s140-s141. DOI: 10.1016/j.jagp.2019.01.094.
- Ochs-Ross R, Daly E, Zhang Y, Lane R, Lim P, Foster K, Hough D, Manji H, Drevets W, Sanacora G, Adler C, McShane R, Gaillard R, Singh J. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression. European Neuropsychopharmacology 2019, 29: s355-s356. DOI: 10.1016/j.euroneuro.2018.11.548.
- Wajs E, Leah A, Morrison R, Daly E, Lane R, Lim P, Holder R, Sanacora G, Young A, Kasper S, Sulaiman A, Li C, Paik J, Manji H, Hough D, Drevets W, Singh J. Long-term safety of esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: SUSTAIN-2 phase 3 study. European Neuropsychopharmacology 2019, 29: s44-s45. DOI: 10.1016/j.euroneuro.2018.11.1016.
- Sanacora G, Kitay B, Wilkinson S. Chapter 35 The Search for Rapid Acting Antidepressants: Research Synthesis and Perspectives. 2019, 401-413. DOI: 10.1016/b978-0-12-813333-0.00035-4.
- Wajs E, Aluisio L, Morrison R, Daly E, Lane R, Lim P, Holder R, Sanacora G, Young A, Kasper S, Sulaiman A, Li C, Paik J, Manji H, Hough D, Drevets W, Singh J. Etude de phase 3 en ouvert évaluant l’efficacité et la sécurité d’emploi à long terme d’Eskétamine intranasal (ESK IN) associé à un antidépresseur oral chez des patients atteints de dépression résistante (SUSTAIN-2). French Journal Of Psychiatry 2018, 1: s176. DOI: 10.1016/s2590-2415(19)30445-3.
- Ochs-Ross R, Daly E, Zhang Y, Lane R, Lim P, Foster K, Hough D, Manji H, Drevets W, Sanacora G, Adler C, McShane R, Gaillard R, Singh J. S114. Efficacy and Safety of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression. Biological Psychiatry 2018, 83: s391. DOI: 10.1016/j.biopsych.2018.02.1005.
- Wilkinson S, Webler R, Katz R, Toprak M, Ostroff R, Sanacora G. S106. Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital. Biological Psychiatry 2018, 83: s388. DOI: 10.1016/j.biopsych.2018.02.997.
- Sanacora G, Wilkinson S, Van Schalkwyk G. 201 Measuring Dissociative Effects of NMDA Receptor Antagonists in the Treatment of Depression. Biological Psychiatry 2017, 81: s83. DOI: 10.1016/j.biopsych.2017.02.214.
- Dwyer J, Sanacora G, Bloch M. 1002 Ketamine as a Treatment for Adolescent Major Depressive Disorder. Biological Psychiatry 2017, 81: s405. DOI: 10.1016/j.biopsych.2017.02.729.
- Sanacora G, Chowdhury G, Rothman D, Behar K. 662 Ketamine and Rapastinel Effects on Glutamate Cycling. Biological Psychiatry 2017, 81: s268. DOI: 10.1016/j.biopsych.2017.02.1071.
- Ostroff R, Wilkinson S, Sanacora G. Computer-assisted cognitive behavior therapy to prevent relapse following electroconvulsive therapy. Brain Stimulation 2017, 10: 524. DOI: 10.1016/j.brs.2017.01.529.
- Hermes G, Sanacora G. Ketamine’s Mechanisms of Rapid Antidepressant Activity: Evidence from Preclinical Studies. 2016, 73-98. DOI: 10.1007/978-3-319-42925-0_6.
- Sanacora G, Heimer H, Hartman D, Mathew S, Frye M, Nemeroff C, Robinson Beale R. Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders. Neuropsychopharmacology 2016, 42: 1179-1181. PMID: 27640324, PMCID: PMC5437876, DOI: 10.1038/npp.2016.193.
- Krystal J, Sanacora G, Abdallah C, Duman R. Speaker 4: John Krystal, USA. The International Journal Of Neuropsychopharmacology 2016, 19: 19-19. PMCID: PMC5616528, DOI: 10.1093/ijnp/pyw042.052.
- Singh J, Fedgchin M, Daly E, De Boer P, Cooper K, Lim P, Pinter C, Murrough J, Sanacora G, Shelton R, Kurian B, Winokur A, Fava M, Manji H, Drevets W, Van Nueten L. P.2.b.017 Onset of efficacy of ketamine in treatment-resistant depression: a double-blind, randomised, placebo-controlled, dose frequency study. European Neuropsychopharmacology 2014, 24: s387-s388. DOI: 10.1016/s0924-977x(14)70618-2.
- Kiselycznyk C, Sanacora G. Using Our Understanding of Stress-Related Effects on Glutamate Neurotransmission to Guide the Development of Novel Treatment Strategies. 2014, 313-341. DOI: 10.1007/978-1-4939-1056-4_17.
- Sanacora G, Duman R. The Revolution in Rapid-Acting Antidepressants. Biological Psychiatry 2013, 73: 1123-1124. DOI: 10.1016/j.biopsych.2013.04.020.
- Abdallah CG, Fasula M, Kelmendi B, Sanacora G, Ostroff R. Rapid Antidepressant Effect of Ketamine in the Electroconvulsive Therapy Setting. Journal Of Ect 2012, 28: 157-161. PMID: 22847373, PMCID: PMC3426617, DOI: 10.1097/yct.0b013e31824f8296.
- Laje G, Lally N, Mathews D, Brutsche N, Chemerinski A, Akula N, Kelmendi B, Simen A, McMahon FJ, Sanacora G, Zarate C. Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Antidepressant Efficacy of Ketamine in Depressed Patients. Biological Psychiatry 2012, 72: e27-e28. PMID: 22771240, PMCID: PMC3786174, DOI: 10.1016/j.biopsych.2012.05.031.
- Morgan PT, Pace-Schott EF, Mason GF, Forselius E, Fasula M, Valentine GW, Sanacora G. Cortical GABA Levels in Primary Insomnia. Sleep 2012, 35: 807-814. PMID: 22654200, PMCID: PMC3353043, DOI: 10.5665/sleep.1880.
- Chowdhury GM, Behar KL, Cho W, Thomas MA, Rothman DL, Sanacora G. 1H-[13C]-Nuclear Magnetic Resonance Spectroscopy Measures of Ketamine's Effect on Amino Acid Neurotransmitter Metabolism. Biological Psychiatry 2011, 71: 1022-1025. PMID: 22169441, PMCID: PMC3660962, DOI: 10.1016/j.biopsych.2011.11.006.
- Popoli M, Yan Z, McEwen BS, Sanacora G. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nature Reviews Neuroscience 2011, 13: 22-37. PMID: 22127301, PMCID: PMC3645314, DOI: 10.1038/nrn3138.
- Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B, Krystal JH, Sanacora G. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS. Psychiatry Research 2011, 191: 122-127. PMID: 21232924, PMCID: PMC3061550, DOI: 10.1016/j.pscychresns.2010.10.009.
- Sanacora G, Banasr M, Chowdhury G, Lepak A, Behar K. S.28.05 Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioural deficits by the glutamate-modulating drug riluzole. European Neuropsychopharmacology 2010, 20: s208. DOI: 10.1016/s0924-977x(10)70241-8.
- Banasr M, Chowdhury GM, Terwilliger R, Newton SS, Duman RS, Behar KL, Sanacora G. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Molecular Psychiatry 2008, 15: 501-511. PMID: 18825147, PMCID: PMC3347761, DOI: 10.1038/mp.2008.106.
- Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews Drug Discovery 2008, 7: 426-437. PMID: 18425072, PMCID: PMC2715836, DOI: 10.1038/nrd2462.
- Neumeister A, Charney D, Sanacora G, Krystal J. Neurobiology and Treatment of Depression. 2007 DOI: 10.1002/9780470101001.hcn018.
- Sanacora G. Evidence for GABAergic and Glutamatergic Involvement in the Pathophysiology and Treatment of Depressive Disorders. 2002, 739-749. DOI: 10.1002/0470854871.chxviii3.
- Krystal J, D'Souza D, Sanacora G, Goddard A, Charney D. CURRENT PERSPECTIVES ON THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA, DEPRESSION, AND ANXIETY DISORDERS. Medical Clinics Of North America 2001, 85: 559-577. PMID: 11349473, DOI: 10.1016/s0025-7125(05)70329-1.
- Chen A, Shin K, Duman R, Sanacora G. ECS-Induced Mossy Fiber Sprouting and BDNF Expression Are Attenuated By Ketamine Pretreatment. Journal Of Ect 2001, 17: 27-32. PMID: 11281511, DOI: 10.1097/00124509-200103000-00006.
- Berman R, Sanacora G, Narasimhan M, Oren D, Cappiello A, Charney D. 268. Simultaneous catecholamine and indoleamine depletion in unmedicated depressed subjects. Biological Psychiatry 2000, 47: s81. DOI: 10.1016/s0006-3223(00)00532-1.
- Berman R, Narasimhan M, Sanacora G, Miano A, Hoffman R, Hu X, Charney D, Boutros N. A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression. Biological Psychiatry 2000, 47: 332-337. PMID: 10686268, DOI: 10.1016/s0006-3223(99)00243-7.
- Sanacora G, Mason G, Krystal J. Impairment of GABAergic Transmission in Depression: New Insights from Neuroimaging Studies. Critical Reviews In Neurobiology 2000, 14: 23. PMID: 11253954, DOI: 10.1615/critrevneurobiol.v14.i1.20.
- Sanacora G, Rothman D, Krystal J. Applications of Magnetic Resonance Spectroscopy to Psychiatry. The Neuroscientist 1999, 5: 192-196. DOI: 10.1177/107385849900500316.
- Sanacora G, Chen A, Shin K, Duman R. 8. Ketamine Effects on ECS Induced BDNF Expression and Mossy Fiber Sprouting. Journal Of Ect 1999, 15: 109. DOI: 10.1097/00124509-199903000-00028.
- Sanacora G, Mason G, Rothman D, Berman R, Charney D, Ciarcia J, Krystal J. 1. ECT Effects on Cortical GABA Levels as Determined by 1H-MRS. Journal Of Ect 1999, 15: 102. DOI: 10.1097/00124509-199903000-00009.
- Malison R, Price L, Berman R, van Dyck C, Pelton G, Carpenter L, Sanacora G, Owens M, Nemeroff C, Rajeevan N, Baldwin R, Seibyl J, Innis R, Charney D. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography. Biological Psychiatry 1998, 44: 1090-1098. PMID: 9836013, DOI: 10.1016/s0006-3223(98)00272-8.
- Berman R, Boutros N, Narasimhan M, Sanacora G, Charney D. 322. Transcranial magnetic stimulation in treatment-refractory depression. Biological Psychiatry 1998, 43: s97. DOI: 10.1016/s0006-3223(98)90770-3.
Departments and Programs
Locations
1
Clinical Neuroscience Research Unit
Connecticut Mental Health Center
34 Park Street
New Haven, CT 06519
1 of 3
- Clinical Neuroscience Research UnitConnecticut Mental Health Center34 Park StreetNew Haven, CT 06519
- Yale Depression Research Clinic100 York StreetSte 2JNew Haven, CT 06511
- Interventional PsychiataryYale New Haven Hospital - West Pavilion1 Park StreetNew Haven, CT 06510
1
Clinical Neuroscience Research Unit
Connecticut Mental Health Center
34 Park Street
New Haven, CT 06519
1 of 3
- Clinical Neuroscience Research UnitConnecticut Mental Health Center34 Park StreetNew Haven, CT 06519
- Yale Depression Research Clinic100 York StreetSte 2JNew Haven, CT 06511
- Interventional PsychiataryYale New Haven Hospital - West Pavilion1 Park StreetNew Haven, CT 06510